# Mutation interactions of BRAF and TP53 define novel prognostic stratification and therapeutic implications in papillary thyroid carcinoma

## TL;DR

This study identifies how BRAF and TP53 mutations influence outcomes in thyroid cancer, offering a new way to predict risk and guide treatment.

## Contribution

The study introduces a mutation-guided framework combining BRAF/TP53 status with staging to improve thyroid cancer risk prediction and treatment strategies.

## Key findings

- BRAF mutations predict recurrence risk and correlate with improved survival in papillary thyroid carcinoma.
- TP53 mutations are more common in advanced thyroid cancers and BRAF mutations are mutually exclusive with RET/NRAS mutations.
- Pathway analysis suggests a shift from MAPK to PI3K/NOTCH activation in advanced thyroid cancers, indicating potential for mTOR inhibitors.

## Abstract

Papillary thyroid carcinoma (PTC) requires improved risk stratification through molecular profiling, yet how mutation interactions shape clinical outcomes remains poorly defined.

This single-center retrospective study analyzed 72 PTC cases using next-generation sequencing to characterize mutation patterns and pathway evolution, with validation against The Cancer Genome Atlas datasets.

We identified three key molecular features: BRAF mutations (47.2%) predicted recurrence risk (p < 0.001), TP53 mutations (15.3%) were more prevalent in advanced thyroid cancers, and mutual exclusivity between BRAF and RET/NRAS mutations (p < 0.01), defining distinct oncogenic pathways. Paradoxically, BRAF mutations correlated with survival improvement (hazard ratio = 0.397), challenging conventional prognostic models. Pathway analysis revealed a potential shift from MAPK dominance in PTC to PI3K/NOTCH activation in advanced thyroid cancers, suggesting targetable vulnerabilities for mTOR inhibitors.

By integrating BRAF/TP53 status with conventional staging, we establish a mutation-guided framework that may refine risk prediction and inform treatment strategies, bridging molecular heterogeneity with clinical decision-making. This work provides insights for personalizing thyroid cancer management.